Amoxapine elevates serum prolactin in depressed men.

Area of Science:

• Psychopharmacology
• Neuroendocrinology
• Clinical Psychiatry

Background:

• Amoxapine, an antidepressant, has been anecdotally suggested to possess neuroleptic properties.
• Neuroleptic medications typically increase serum prolactin due to dopamine D2 receptor blockade.
• Major depressive disorder (MDD) is a prevalent psychiatric condition often requiring multifaceted treatment approaches.

Purpose of the Study:

• To investigate the potential neuroleptic (antipsychotic) properties of amoxapine.
• To assess the effect of amoxapine on serum prolactin levels in patients with major depression.
• To compare amoxapine's effect on prolactin with a non-neuroleptic antidepressant, desipramine.

Main Methods:

• Ten male patients diagnosed with major depression (DSM-III criteria) were treated with amoxapine.
• Serum prolactin levels were measured and compared to drug-free baseline values.
• A comparison group of 12 depressed males received desipramine, with similar prolactin measurements taken.

Main Results:

• Amoxapine treatment resulted in a statistically significant increase in serum prolactin levels compared to baseline.
• Depressed men treated with desipramine did not exhibit a significant change in serum prolactin.
• These findings align with the known effects of neuroleptic medications on prolactin.

Conclusions:

• The observed increase in serum prolactin suggests amoxapine possesses neuroleptic (antipsychotic) properties.
• Amoxapine may be a valuable therapeutic option for patients requiring combined antidepressant and antipsychotic effects.
• Further research is warranted to confirm amoxapine's efficacy in treating conditions with comorbid depressive and psychotic symptoms.